Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 23:16:205-214.
doi: 10.2147/RRU.S477396. eCollection 2024.

The Etiology and Pathogenesis of Benign Prostatic Hyperplasia: The Roles of Sex Hormones and Anatomy

Affiliations
Review

The Etiology and Pathogenesis of Benign Prostatic Hyperplasia: The Roles of Sex Hormones and Anatomy

Ganzhe Xu et al. Res Rep Urol. .

Abstract

Benign prostatic hyperplasia (BPH) mainly causes lower urinary tract symptoms in ageing men, but its exact etiology and pathogenesis have not been established. The objective of this review was to design an update on the advances of human BPH research. We undertook a literature search for identifying studies of the roles of sex hormones (androgens and estrogens) in the onset and development of human BPH using the Pubmed database. In literature, many studies have indicated that ageing and obesity are the factors for preceding the onset of BPH. No evidence for the role of testosterone (T) or dihydrotestosterone (DHT) is found in BPH initiation. Since BPH exclusively occurs in the transitional zone (TZ) surrounding the urethra, it is postulated that years of exposure to uncharacterized urinary toxins could disrupt the homeostasis of the stroma and/or epithelium of this prostatic zone that are typically occurring in ageing men. After cellular damage and subsequent inflammation generated, the intraprostatic DHT produced mainly from T by 5α-reductase promotes BPH development. Further, estrogens could take part in the nodular proliferation of stromal cells in some BPH patients. The confounding of BPH may attenuate the development of prostate tumor in the TZ. In conclusion, evidence in literature suggests that androgens are not etiological factors for BPH, and intraprostatic DHT along with chronic inflammation are mainly responsible for nodular proliferation of stromal and/or epithelial cells in prostatic TZ. The urinary factors for the etiology of BPH and BPH as a prediction of PCa progression still need further investigation.

Keywords: androgens; benign prostatic hyperplasia; epithelium; etiology; nodular proliferation; steroid sex hormones; stroma; tissue homeostasis.

PubMed Disclaimer

Conflict of interest statement

All authors have no competing interest to declare.

Figures

Figure 1
Figure 1
The phase diagram of BPH development (etiology and pathogenesis) with age. At a young age, the functional organization of prostatic tissues including transitional zone (TZ), central zone (CZ), peripheral zone (PZ), urethra, and ejaculatory duct is well maintained by tissue homeostasis. At a middle age, after years of exposure to the waste chemicals from the urine, the tissue homeostasis of TZ is disrupted by accumulation of urinary wastes within the TZ and leukocyte infiltration (the onset of BPH) (hypothesis). From the middle to old age, after irreversible disruption of tissue homeostasis, inflammatory mediators induce cell death and fibrosis, while locally synthesized DHT and growth factors stimulate cell proliferation – to form epithelial hyperplasia (EH) and stromal hyperplasia (SH), which may represent different subtypes of TZ enlargement and lead to urethra obstruction.

Similar articles

Cited by

References

    1. Roehrborn CG. Acute urinary retention: risks and management. Rev Urol. 2005;7(Suppl 4):S31–S41. - PMC - PubMed
    1. Stewart KL, Lephart ED. Overview of BPH: symptom relief with dietary polyphenols, vitamins and phytochemicals by nutraceutical supplements with implications to the prostate microbiome. Int J Mol Sci. 2023;24(6):5486. doi:10.3390/ijms24065486 - DOI - PMC - PubMed
    1. Launer BM, McVary KT, Ricke WA, et al. The rising worldwide impact of benign prostatic hyperplasia. BIU Int. 2021;127:722–728. - PMC - PubMed
    1. Awedew AF. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Health Longev. 2022;3(11):e754–e776. doi:10.1016/S2666-7568(22)00213-6 - DOI - PMC - PubMed
    1. Roehrborn CG. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia. Int J Impot Res. 2008;20(3):S19–S26. doi:10.1038/ijir.2008.53 - DOI - PubMed

LinkOut - more resources